Here is another post from JD. I have copied from Stockhouse.
When reading the post, keep in mind there is reference to idiots that know nothing about BTI and the Science (princeofcut, San Fran, etc) who JD has referred to in his post. Get past that, and pay attention to the billion dollar market and more importantly BTIs planned business model.
Here it is:
Well, let me explain! biOasis's Transcend (MTfp) is a platform technology, not a therapeutic. It does not treat brain diseases. Instead, it transports the treatments into the brain and, so far, it's the most able and safe means of doing so.
MTfp is a small peptide (short string of amino acids) with the ability to seek out and attach itself to the melanotransferrin (MTf) receptor on the endothelial cells of the brain's capillaries, otherwise known as the blood-brain barrier. Upon attachment to the BBB cells' MTf receptors, the BBB cells pull the peptide through the BBB cells and into the brain's parenchyma (the place where braincells reside). The MTfp peptide can be attached to almost any therapeutic from small molecules to full-sized proteins (such as monoclonal antibodies). If so attached then the MTfp peptide will also pull the therapeutic into the brain, thus delivering therapeutic into the brain parenchyma.
It has been estimated that if such a vector could be found, the resulting neurotherapeutic commercial markets could exceed $100 billion per year, which makes sense when we consider the need for treatments for brain tumours, Alzheimer's, Parkinsons, ALS, pain, metabolic disorders like Lysosomal Storage Diseases, etc. The need is huge and almost completely unmet.
Here's where princeofcut has so woefully fallen behind in his knowledge. biOasis and several pharmaceutical companies have identified about 200 therapeutics (for a host of indications) that MTfp can deliver to the brain. biOasis has chosen a couple of them to do in-house with the objective of keeping them and taking them into human clinical trials. The first is Herceptin. In separate animal models (studies), first at Texas Tech University with the chemical conjugate, MTf-TZM, and then at OncoDesign in France with the fusion protein, MTfp-TZM, biOasis was able to reduce HER2+ breast cancer brain metastases volume by over 85%. Herceptin alone could only achieve a 15% reduction in volume in brain tumours. biOasis has chosen to take this new drug, MTfp-TZM, into human trials.
Meanwhile, biOasis is doing a study in Italy with Enzyme Replacement Therapy for Lysosomal Storage diseases. Although biOasis may take this program into the clinic, it's more likely that biOasis could sell that program, possibly in the next few days or weeks. (It's worth $500 million to a billion, some say more, to biOasis.)
But the real business for biOasis, the one that princeofcut missed, is the BBB vector licensing business. It involves the other almost 200 therapeutics that biOasis has identified that require transport to the brain. They include new drugs for pain, Alzheimer's, MS, ALS, other types of brain cancer, etc etc.
Here's how it works. The pharmaceutical companies want to take these drugs into the clinic and eventually to commercialize them. They cannot do that unless they find a means of transporting them into the brain. Because biOasis has such a vector, MTfp, the only serious alternative, the pharmaceutical companies must use it for all of their neurotherapeutic studies and clinical trials.
And that means that biOasis will be generating revenue, probably a lot of it, before a single neurotherapeutic goes into human clinical trials. It's simple. The pharmas cannot get efficacious (or sufficiently efficacious) quantities of their neurotherapeutics across the BBB but biOasis can. They have to license MTfp in order to advance their drugs. They have to pay for that license. Moreover, it appears that most of them want exclusivity for particular indications. Imagine how much they'll have to pay to exclude their competitors for each disease! We'll discuss that as soon as SanFrancisco99 invites me again.
In short, unlike most biotechs, including RVX, biOasis will be paid by pharmas before anything goes into human trials. They must pay biOasis to take their neurotherapeutics into human trials. (That is the answer to your question G1945V.)
Investors here might want to investigate the possibilities and likely timetable for expected upcoming biOasis developments.
Meanwhile, I have to recognize BearDownAZ's excellent post earlier here. BearDownAZ is an interesting fellow. It has been clear from his RVX posts that he has extensive scientific knowledge and experience. Followers here, including SanFrancisco99, have applauded his many comments about Resverlogix. Although I was very pleased to see him starting to offer comments on the biOasis forum, I was even more pleased with his open-mindedness in the face of the attacks that biOasis has suffered on this forum. BearDownAZ is an independent thinker. But even more compelling was his recent announcement on the biOasis forum that he is a neuroscientist. He already knows about Receptor Mediated Transcytosis (or endocytosis, as he called it earlier). He understands the world of monoclonal antibodies like TZM (Trastuzumab or Herceptin). He just gets it. That understanding is going to make him some money, lots we think. As he stated, we did talk by phone. I asked him whether he was aware of a scientific paper that was produced at his University that related to a certain type of Receptor Mediated Transcytosis. He immediately named the author and details of the paper. BearDownAZ is who he says he is.
Princeofcut, the narcissistic, mirror-gazing, bombast blatherskite, also says something about clinical trials but he is completely unable to place the trial he references in the context of any of the three elements of biOasis's business models. With so many "ignores," who cares what he writes, much less what he thinks.
SanFrancisco99's comments about about me suggest that I post under three aliases. He's done this before. I have posted on the RVX forum for 10 years and during that time I posted first as "amorak", then "RiskyStox" and finally as "jdstox." I never used any of the aliases concurrently. With each change, I immediately announced the cancellation of the old one and the adoption of the new one. And that is part of the record, as SF99 well knows. His dishonestly is very evident on the issue.
SanFransisco99 has also used the word "scam" in his discussion of biOasis. If biOasis is a scam then The National Research Council of Canada, The University of British Columbia, Texas Tech University, MedImmune, Abbvie, Shire, UCB, Merck, Pfizer Canada, AstraZeneca, Quebec Ministry of Economy, Innovation and Exports (MEIE), CQDM, Brain Canada, Government of Canada, Ontario's Centres of Excellence, Brains for Brain Foundation and a host of other corporations and institutions are all in on the scam. What a conspiracy! For the record, all of biOasis's in vivo studies have been conducted by third parties such as Texas Tech, UBC, NRC, OncoDsign, etc. And biOasis was recently awarded $2.6 million by CQDM for BBB Single Domain Antibody vector research. Go look at who CQDM is.
